NCT02199665 2025-11-03
SINE
University of Chicago
Phase 1 Completed
Clinical Trials
24 trialsNCT04850755 2025-09-25
A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies
National University Hospital, Singapore
Phase 1 Completed
NCT02303392 2025-06-10
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT04811196 2025-05-29
A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
University Health Network, Toronto
Phase 1 Completed
NCT02323880 2025-01-14
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Children's Oncology Group
Phase 1 Completed
NCT03955783 2024-10-26
Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT01896505 2024-01-08
A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma
Karyopharm Therapeutics Inc
Phase 1 Completed
NCT02299518 2023-06-15
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02120222 2023-04-04
KPT-330
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01607892 2023-01-26
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
Karyopharm Therapeutics Inc
Phase 1 Completed
NCT01607905 2023-01-26
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Karyopharm Therapeutics Inc
Phase 1 Completed
NCT02403310 2022-10-03
A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02471911 2022-04-12
KPT-330+RICE
Weill Medical College of Cornell University
Phase 1 Completed
NCT03042819 2021-12-09
Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas
University Health Network, Toronto
Phase 1 Completed
NCT02741388 2021-12-07
SELINDA
The Lymphoma Academic Research Organisation
Phase 1 Completed
NCT02485535 2021-05-13
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
University of Chicago
Phase 1 Completed
NCT03212937 2021-04-28
Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma
National Cancer Centre, Singapore
Phase 1 Completed
NCT02269293 2021-04-23
Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02831686 2020-11-24
A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02078349 2020-09-10
Phase I Study of KPT330 in Asian Patients
National University Hospital, Singapore
Phase 1 Completed
NCT03661515 2020-05-20
FLAGINEXOR
PETHEMA Foundation
Phase 1 Completed
NCT02573363 2020-04-08
Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
University of Chicago
Phase 1 Completed
NCT02212561 2020-03-26
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
St. Jude Children's Research Hospital
Phase 1 Completed
NCT02093403 2017-12-08
Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Completed